Evidence map›Paper›PMID 34807364›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2022

Performance of the eazyplex® BloodScreen GN as a simple and rapid molecular test for identification of Gram-negative bacteria from positive blood cultures.

Katharina Bach, Birgit Edel, Steffen Höring, Lucie Bartoničkova, Stefan Glöckner, Bettina Löffler, Christina Bahrs, Jürgen Rödel

Open access · hybridAbstract read
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. [Requirements for the rational use of antibiotics based on antibiotic stewardship].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026
    Review
  2. Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Point-of-Care Method T2BacteriaMicroorganisms · 2024
    Article
  7. The Evaluation of EazyplexAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Katharina BachInstitute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Birgit EdelInstitute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Steffen HöringDivision of Infection Control and Infectious Diseases, RWTH Aachen University Hospital, Aachen, Germany.
Lucie BartoničkovaInstitute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Stefan GlöcknerInstitute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Bettina LöfflerInstitute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Christina BahrsInstitute for Infectious Diseases and Infection Control, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Jürgen RödelInstitute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University, Jena, Germany. juergen.roedel@med.uni-jena.de.
Jena University Hospital · DEFriedrich Schiller University Jena · DEMedical University of Vienna · ATUniversitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The LAMP-based eazyplex® BloodScreen GN was evaluated for the detection of frequent Gram-negatives directly from positive blood culture (BC) bottles. A total of 449 BCs were analyzed. Sensitivities and specificities were 100% and 100% for Escherichia coli, 95.7% and 100% for Klebsiella pneumoniae, 100% and 100% for bla

Indexed as

BacteremiaEscherichia coli InfectionsBlood CultureGram-Negative BacteriaHumansBlood cultureGram-negative bacilliLAMPRapid diagnosticsSepsis

Identifiers

PMID34807364
PMCPMC8831353
OpenAlexW3216124589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.